Josh P. Roberts
Genetic Engineering & Biotechnology News, November 15, 2024.
Abstract:
The COVID-19 pandemic has accelerated interest in mRNA technologies, particularly in improving the manufacturing processes for mRNA-based vaccines. This article explores advancements presented at the 2024 mRNA Technology Conference, focusing on innovative approaches to mRNA production and purification. A key highlight is the work of Aleš Štrancar, PhD, from Sartorius BIA Separations, who emphasizes the importance of using orthogonal analytical methods to assess lipid nanoparticle (LNP) encapsulation efficiency. Štrancar explains that mRNA, being unstable and vulnerable to RNAses, needs protection by being enveloped in lipids to form LNPs. However, LNPs can be heterogeneous, affecting vaccine safety and efficacy. He recommends using capillary electrophoresis and liquid chromatography/UV spectroscopy to improve quality control and gain insights into LNP formation. This comprehensive approach not only enhances batch-to-batch consistency but also aids in selecting less immunogenic lipids. One way to implement this strategy is to use Sartorius’s PATfix Switcher method alongside established methods recognized by regulatory bodies. For further insights into these developments and more, read the full article.
